Anticoagulation for HIT II: When should it be used Therapeutically and when as Prophylaxis?;Antikoagulation bei HIT II: Wann therapeutisch - Wann prophylaktisch?

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie, Supplement

Volumn 37, Issue 1, 2002, Pages 3-7

  Greinacher, Andreas ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; HEPARIN; HIRUDIN; LEPIRUDIN;

ANTICOAGULATION; ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG INDICATION; HEPARIN INDUCED THROMBOCYTOPENIA TYPE 2; HUMAN; INCIDENCE; PATHOPHYSIOLOGY; PROPHYLAXIS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0036272614     PISSN: 14307790     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-25156     Document Type: Article

References (22)

1. Clinical picture of heparin-induced thrombocytopenia
2. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases
3. Pathogenicity of IgA and/or IgM antibodies to heparin-PF-4 complexes in patients with heparine-induced thrombocytopenia
4. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
5. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
6. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation
7. A 14-year study of heparin-induced thrombocytopenia
8. Heparin-induced thrombocytopenia: Mechanisms of interaction of the heparin-dependent antibody with platelets
9. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
10. Immune endothelial-cell injury in heparin-associated thrombocytopenia
11. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparine-induced thrombocytopenia
12. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
13. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
14. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
15. Limitations of conventional treatment options for heparin-induced thrombocytopenia
16. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
17. Impact of the patient population on the risk for heparin-induced thrombocytopenia
18. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
19. Heparin-induced thrombocytopenia and thrombosis
20. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia
21. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
22. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: Absence of an anamnestic immune response, and implications for repeat use in patients with a history of HIT